The mutational repertoire of cancers creates the neoepitopes that make cancers
immunogenic. Here, we introduce two novel tools that identify, with relatively high accuracy …

Immune checkpoint blockade has been largely unsuccessful for the treatment of bone
metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a combinatorial …

Abstract Background and Aims: Molecular classification is a promising tool for prognosis
prediction and optimizing precision therapy for HCC. Here, we aimed to develop a molecular …

Background Oncolytic viruses are among the most powerful and selective cancer
therapeutics under development and are showing robust activity in clinical trials, particularly …

Breast cancer metastasis is the leading cause of cancer-related deaths in women
worldwide. Collagen in the tumor microenvironment plays a crucial role in regulating tumor …

High-affinity MHC I-peptide interactions are considered essential for immunogenicity.
However, some neo-epitopes with low affinity for MHC I have been reported to elicit CD8 T …

Heterotypic cellular and molecular interactions in the tumor microenvironment (TME) control
cancer progression. Here, we show that CD1d-restricted invariant natural killer (iNKT) cells …

Cytokine-induced killer (CIK) cells raised interest for use in cellular antitumor therapy due to
their capability to recognize and destroy autologous tumor cells in a HLA-independent …

Viral infections lead to alarmin release and elicit potent cytotoxic effector T lymphocyte
(CTLeff) responses. Conversely, the induction of protective tumour-specific CTLeff and their …

Chimeric antigen receptor (CAR)-redirected T cell therapy often fails to control tumors in the
long term due to selecting cancer cells that downregulated or lost CAR targeted antigen. To …